Table 2 Representative clinical trials with CAR-NK cells.
From: Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
No. | Study Title | NCT Number | Status | Conditions | Interventions |
|---|---|---|---|---|---|
1 | NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT05247957 | Terminated | Safety and Efficacy | CAR-NK cells |
2 | A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 | NCT04324996 | Unknown status | COVID-19 | NK cells, IL15-NK cells, NKG2D CAR-NK cells, ACE2 CAR-NK cells, NKG2D-ACE2 CAR-NK cells |
3 | Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia | NCT05574608 | Recruiting | Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Recurrent | CD123-CAR-NK cells |
4 | The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT05673447 | Recruiting | Diffuse Large B Cell Lymphoma | CD19 CAR NK cells |
5 | Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer | NCT05507593 | Recruiting | SCLC, Extensive Stage | DLL3-CAR-NK cells |
6 | CLDN6-CAR-NK Cell Therapy for Advanced Solid Tumors | NCT05410717 | Recruiting | Stage IV Ovarian Cancer Testis Cancer, Refractory Endometrial Cancer Recurrent | Claudin6 targeting CAR-NK cells |
7 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | NCT05410041 | Recruiting | Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Non Hodgkin Lymphoma | CAR-NK-CD19 Cells |
8 | Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma | NCT03692767 | Unknown status | Refractory B-Cell Lymphoma | CD22 CAR NK Cells |
9 | Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma | NCT03690310 | Unknown status | Refractory B-Cell Lymphoma | CD19 CAR NK Cells |
10 | CAR-NK Targeted CD19 for r/r B-cell Malignancies | NCT05645601 | Recruiting | Adult Relapsed/Refractory B-cell Hematologic Malignancies | CD19-CAR-NK cells |
11 | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies | NCT05739227 | Recruiting | Acute Lymphoblastic Leukemia B-cell Lymphoma Chronic Lymphocytic Leukemia | CD19-CAR-NK cells |
12 | NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer | NCT05213195 | Recruiting | Refractory Metastatic Colorectal Cancer | NKG2D CAR-NK cells |
13 | Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia | NCT05987696 | Not yet recruiting | AML, Adult Minimal Residual Disease | CD33/CLL1 dual CAR-NK cells Cyclophosphamid Fludarabine |
14 | NKG2D CAR-NK & Ovarian Cancer | NCT05776355 | Recruiting | Ovarian Cancer | NKG2D CAR-NK cells |
15 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia | NCT05563545 | Completed | Acute Lymphoblastic Leukemia | CAR-NK-CD19 Cells |
16 | NKG2D CAR-NK & r/rAML | NCT05734898 | Recruiting | AML | NKG2D CAR-NK cells |
17 | Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours | NCT03415100 | Unknown status | Solid Tumours | CAR-NK cells targeting NKG2D ligands |
18 | Clinical Study of the Safety and Efficacy of BCMA CAR-NK | NCT05652530 | Recruiting | Immunotherapy Multiple Myeloma | BCMA CAR-NK cells |
19 | Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer | NCT03941457 | Unknown status | Pancreatic Cancer | BiCAR-NK cells (ROBO1 CAR-NK cells) |
20 | Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL | NCT04887012 | Recruiting | B-cell Non Hodgkin Lymphoma | CD19 CAR-NK cells |
21 | Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL | NCT05472558 | Recruiting | B-cell Non Hodgkin Lymphoma | CD19 CAR-NK cells |
22 | Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors | NCT03940820 | Unknown status | Solid Tumor | ROBO1 CAR-NK cells |
23 | Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | NCT06006403 | Recruiting | Acute Myeloid Leukemia Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Relapse Leukemia | CD123 targeted CAR-NK cells |
24 | Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies | NCT05570188 | Withdrawn | B-cell Lymphoma B-cell Leukemia | CD19 UCAR-NK cells |
25 | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33 + AML | NCT02944162 | Unknown status | Acute Myelogenous Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia With Maturation | CD33 CAR-NK cells |
26 | An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus | NCT06010472 | Recruiting | Systemic Lupus Erythematosus (SLE) | CD19 CAR NK cells (KN5501) |
27 | Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor | NCT03931720 | Unknown status | Malignant Tumor | BiCAR-NK/T cells |
28 | Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors | NCT05194709 | Recruiting | Advanced Solid Tumors | 5T4-CAR-NK Cells |
29 | Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM | NCT03940833 | Unknown status | Multiple Myeloma | BCMA CAR-NK 92 cells |
30 | Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma | NCT03824964 | Unknown status | Refractory B-Cell Lymphoma | Anti-CD19/CD22 CAR NK Cells |
31 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | NCT02892695 | Unknown status | Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Follicular Lymphoma | CD19 CAR-NK cells |
32 | Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia | NCT05215015 | Recruiting | Acute Myeloid Leukemia | CD33/CLL1 CAR-NK Cells |
33 | Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma | NCT05845502 | Not yet recruiting | Advanced Hepatocellular Carcinoma | SZ003 CAR-NK |
34 | Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | NCT04796675 | Recruiting | Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Non Hodgkin’s Lymphoma | Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells |
35 | Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | NCT05008575 | Recruiting | Leukemia, Myeloid, Acute | CD33 CAR NK cells Fludarabine Cytoxan |
36 | Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma | NCT05008536 | Recruiting | Multiple Myeloma, Refractory | BCMA CAR-NK Cells Fludarabine Cytoxan |
37 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | NCT02742727 | Unknown status | Acute Myeloid Leukemia Precursor T-Cell Lymphoblastic Leukemia-Lymphoma T-cell Prolymphocytic Leukemia | CD7 CAR-pNK cells |
38 | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | NCT05922930 | Not yet recruiting | Pancreatic Cancer Ovarian Cancer Adenocarcinoma | TROP2-CAR-NK Cyclophosphamide Fludarabine |
39 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | NCT04623944 | Recruiting | Relapsed/Refractory AML AML, Adult MDS 1 more | NKX101 - CAR NK cell therapy |
40 | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | NCT03056339 | Completed | B-Lymphoid Malignancies Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia | CAR NK cells Fludarabine Cyclophosphamide Mesna |
41 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | NCT05092451 | Recruiting | B-Cell Lymphoma Myelodysplastic Syndromes (MDS) Acute Myeloid Leukemia (AML) | Cyclophosphamide CAR.70/IL15-transduced CB-NK cells Fludarabine phosphate |
42 | Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances | NCT05110742 | Not yet recruiting | Hematological Malignancy | Fludarabine Phosphate Cyclophosphamide CAR.5/IL15-transduced CB-NK cells |
43 | Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer | NCT04847466 | Recruiting | Gastroesophageal Junction (GEJ) Cancers Advanced HNSCC | N-803 Pembrolizumab PD-L1 t-haNK |
44 | Induced-T Cell Like NK Cells for B Cell Malignancies | NCT04747093 | Unknown status | B Cell Leukemia B Cell Lymphoma B-cell Acute Lymphoblastic Leukemia | CAR-ITNK cells |
45 | Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | NCT05667155 | Recruiting | B-cell Non Hodgkin Lymphoma | CB dual CAR-NK19/70 |
46 | A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies | NCT05654038 | Recruiting | B-Cell Lymphoblastic Leukemia/Lymphoma | CD19 UCAR-NK cells |
47 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | NCT05020678 | Recruiting | Lymphoma, Non-Hodgkin B-cell Acute Lymphoblastic Leukemia Large B-cell Lymphoma | NKX019 |
48 | A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | NCT05020015 | Recruiting | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | TAK-007 Chemotherapy Agents |
49 | Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer | NCT03692637 | Unknown status | Epithelial Ovarian Cancer | Mesothelin Car NK Cells |
50 | Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | NCT05842707 | Recruiting | Refractory or Relapsed B-cell Non-Hodgkin Lymphoma | dualCAR-NK19/70 cell |
51 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | NCT02839954 | Unknown status | Hepatocellular Carcinoma Non-small Cell Lung Cancer Pancreatic Carcinoma | MUC1 CAR-pNK cells |
52 | Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. | NCT04639739 | Not yet recruiting | NHL | CD19 CAR NK |
53 | Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies | NCT04796688 | Recruiting | Acute Lymphoblastic Leukemia Chronic Lymphoblastic Leukemia B-cell Lymphoma | Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells |
54 | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma | NCT05703854 | Recruiting | Advanced Renal Cell Carcinoma Advanced Mesothelioma Advanced Osteosarcoma | CAR.70/IL15-transduced CB-derived NK cells Fludarabine phosphate Cyclophosphamide |
55 | FT576 in Subjects With Multiple Myeloma | NCT05182073 | Recruiting | Multiple Myeloma Myeloma | FT576 (Allogenic CAR NK cells with BCMA expression) Cyclophosphamide Fludarabine |
56 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies | NCT05487651 | Recruiting | NHL, Relapsed, Adult B-cell Lymphoma B-cell Leukemia | Genetic: KUR-502 |
57 | Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Ovarian Epithelial Carcinoma | NCT05856643 | Not yet recruiting | Ovarian Epithelial Carcinoma | SZ011 CAR-NK |
58 | Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer | NCT05686720 | Not yet recruiting | Advanced Triple Negative Breast Cancer | SZ011 CAR-NK |
59 | RD13-01 for Patients With r/r CD7 + T/NK Cell Hematologic Malignancies | NCT04538599 | Completed | Hematologic Malignancies | RD13-01 cell infusion |
60 | Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes | NCT02134262 | Unknown status | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Cyclophosphamide or Bendamustine Dose Level 1 Dose Level 1 |
61 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | NCT03579927 | Withdrawn | CD19 Positive Mantle Cell Lymphoma Recurrent Diffuse Large B-Cell Lymphoma | Autologous Hematopoietic Stem Cell Transplantation Carmustine Cytarabine |
62 | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | NCT03692663 | Recruiting | Metastatic Castration-resistant Prostate Cancer | TABP EIC Cyclophosphamide fludarabine |
63 | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies | NCT05336409 | Recruiting | R/R CD19-Positive B-Cell Malignancies Indolent Non-Hodgkin Lymphoma Aggressive Non-Hodgkin Lymphoma | CNTY-101 IL-2 Lymphodepleting Chemotherapy |
64 | Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma | NCT05618925 | Not yet recruiting | Non Hodgkin’s Lymphoma Refractory/Relapsed | N803 CD19 t-haNK suspension Cyclophosphamide |
